Friday, July 10, 2026

Patent intelligence · US

US 6306436

Stabilized, acid-free formulation for sustained release of bupropion hydrochloride

expired A61KA61K31/137A61K9/2013A61K9/2018
Status expired
Linked drugs 1
Pipeline programs 6
Years to expiry 0
Applicant portfolio 454
Patent details — US 6306436
Jurisdiction
US
Status
expired
Grant date
Oct 23, 2001
Expiration
Oct 18, 2021
Claims
36
CPC classes
A61K, A61K31/137, A61K9/2013, A61K9/2018
View on Google Patents ↗

Quick answer

US 6306436 (Stabilized, acid-free formulation for sustained release of bupropion hydrochloride) is held by Teva Pharmaceuticals USA, Inc.. Status: expired. Granted Oct 23, 2001. Expires Oct 18, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
36
CPC classes
A61K, A61K31/137, A61K9/2013, A61K9/2018, A61K9/2027, A61K9/2054

More from Teva Pharmaceuticals USA, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12310929

    Use of rasagiline for the treatment of restless legs syndrome

    TEVA PHARMACEUTICAL INDUSTRIES, LTD. · Expires May 22, 2045

    granted
  2. US 12258401

    Anti-CD47 combination therapy

    TEVA PHARMACEUTICALS AUSTRALIA PTY LTD · Expires Mar 20, 2045

    granted
  3. US 12157729

    Solid state forms of Belumosudil and Belumosudil salts

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Expires Nov 28, 2044

    granted
  4. US 12139528

    Treating refractory migraine

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Expires Nov 7, 2044

    granted
  5. US 12091388

    Solid state forms of Reproxalap

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Expires Sep 12, 2044

    granted
  6. US 11826322

    Pre-filled syringe

    Teva Pharmaceuticals USA, Inc. · Expires Nov 23, 2043

    granted
  7. US 11813359

    Sustained release olanzapine formulations

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Expires Nov 9, 2043

    granted
  8. US 11773083

    Solid state forms of Belumosudil and Belumosudil salts

    TEVA PHARMACEUTICALS INTERNATIONAL GMBH · Expires Sep 28, 2043

    granted

Frequently asked questions

What is US patent 6306436?

US 6306436 (Stabilized, acid-free formulation for sustained release of bupropion hydrochloride) is held by Teva Pharmaceuticals USA, Inc.. Status: expired. Granted Oct 23, 2001. Expires Oct 18, 2021 (0 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 6306436?

Teva Pharmaceuticals USA, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 454 pharmaceutical patents for this assignee.

When does US 6306436 expire?

Our index shows an expiration date of Oct 18, 2021 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.